{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:06:06Z","timestamp":1774047966564,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lfs.2026.124273","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:02:41Z","timestamp":1770969761000},"page":"124273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multidrug resistant non-small cell lung cancer cells exhibiting collateral sensitivity to DNA damaging drugs"],"prefix":"10.1016","volume":"391","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-6368","authenticated-orcid":false,"given":"Sara","family":"Peixoto da Silva","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0521-5655","authenticated-orcid":false,"given":"L\u00facio","family":"Lara Santos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-1917","authenticated-orcid":false,"given":"Cristina","family":"P.R. Xavier","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-4643","authenticated-orcid":false,"given":"M. Helena","family":"Vasconcelos","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124273_bb0005","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2026.124273_bb0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12272-021-01312-y","article-title":"Mechanisms of resistance to chemotherapy in non-small cell lung cancer","volume":"44","author":"Min","year":"2021","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.lfs.2026.124273_bb0015","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lfs.2026.124273_bb0020","article-title":"Current treatments for non-small cell lung cancer","volume":"12","author":"Guo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2026.124273_bb0025","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2026.124273_bb0030","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/cancers16050935","article-title":"Clinical benefit from docetaxel +\/\u2212 ramucirumab is not associated with mutation status in metastatic non-small-cell lung cancer patients who progressed on platinum doublets and immunotherapy","volume":"16","author":"Qin","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2026.124273_bb0035","first-page":"179","article-title":"Chemotherapy for lung cancer in the era of personalized medicine, tuberculosis and respiratory diseases","volume":"82","author":"Lee","year":"2019"},{"key":"10.1016\/j.lfs.2026.124273_bb0040","article-title":"Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations","volume":"3","author":"Liu","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"10.1016\/j.lfs.2026.124273_bb0045","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3390\/cancers16183123","article-title":"Dual-action therapeutics: DNA alkylation and antimicrobial peptides for cancer therapy","volume":"16","author":"Andr\u00e9s","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2026.124273_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107124","article-title":"Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC","volume":"9","author":"Brodie","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2026.124273_bb0055","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.lfs.2026.124273_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22010006","article-title":"Special issue: new approaches to counteract drug resistance in cancer","volume":"22","author":"Vasconcelos","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2026.124273_bb0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/1568009616666151113120705","article-title":"Understanding cancer drug resistance by developing and studying resistant cell line models","volume":"16","author":"Xavier","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.lfs.2026.124273_bb0070","article-title":"Multidrug resistance of cancer cells and the vital role of P-glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life (Basel)."},{"key":"10.1016\/j.lfs.2026.124273_bb0075","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bmc.2016.11.023","article-title":"A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells","volume":"25","author":"Lopes-Rodrigues","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.lfs.2026.124273_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11171","article-title":"P-glycoprotein and cancer: what do we currently know?","volume":"8","author":"Pilotto Heming","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.lfs.2026.124273_bb0085","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1039\/D0QI01344G","article-title":"Unprecedented collateral sensitivity for cisplatin-resistant lung cancer cells presented by new ruthenium organometallic compounds","volume":"8","author":"Teixeira","year":"2021","journal-title":"Inorg. Chem. Front."},{"key":"10.1016\/j.lfs.2026.124273_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177234","article-title":"Isoquinolinequinone N-oxides with diverging mechanisms of action induce collateral sensitivity against multidrug resistant cancer cells","volume":"988","author":"Barbosa","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124273_bb0095","doi-asserted-by":"crossref","first-page":"13909","DOI":"10.1021\/acs.jmedchem.4c00705","article-title":"Discovery of potent isoquinolinequinone N-oxides to overcome cancer multidrug resistance","volume":"67","author":"Kruschel","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2026.124273_bb0100","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1038\/s41598-022-09319-1","article-title":"Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse","volume":"12","author":"Dalin","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2026.124273_bb0105","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ctrv.2007.07.013","article-title":"A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship","volume":"33","author":"Stordal","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lfs.2026.124273_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00599","article-title":"Epoxylathyrane derivatives as MDR-selective compounds for disabling multidrug resistance in cancer","volume":"11","author":"Reis","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124273_bb0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2016.06.002","article-title":"Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines","volume":"305","author":"Ooko","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124273_bb0120","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.3390\/ijms21093333","article-title":"MRP1-collateral sensitizers as a novel therapeutic approach in resistant cancer therapy: an in vitro and in vivo study in lung resistant tumor","volume":"21","author":"Riganti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124273_bb0125","doi-asserted-by":"crossref","first-page":"21473","DOI":"10.1074\/jbc.M114.581702","article-title":"Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin","volume":"289","author":"Hall","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2026.124273_bb0130","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/10715762.2015.1136062","article-title":"Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate","volume":"50","author":"Banerjee","year":"2016","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.lfs.2026.124273_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2021.129915","article-title":"Exploiting the metabolic energy demands of drug efflux pumps provides a strategy to overcome multidrug resistance in cancer","volume":"1865","author":"Gao","year":"2021","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.lfs.2026.124273_bb0140","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00775-017-1498-4","article-title":"A newly synthesized nickel chelate can selectively target and overcome multidrug resistance in cancer through redox imbalance both in vivo and in vitro","volume":"22","author":"Banerjee","year":"2017","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"10.1016\/j.lfs.2026.124273_bb0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1179\/joc.2006.18.1.66","article-title":"Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs","volume":"18","author":"Pesic","year":"2006","journal-title":"J. Chemother."},{"key":"10.1016\/j.lfs.2026.124273_bb0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00280-013-2247-1","article-title":"Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing","volume":"72","author":"Podolski-Reni\u0107","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124273_bb0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","article-title":"Single-pot, solid-phase-enhanced sample preparation for proteomics experiments","volume":"14","author":"Hughes","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.lfs.2026.124273_bb0160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2020.11.013","article-title":"Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine","volume":"501","author":"Xavier","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2026.124273_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030407","article-title":"Proteomics analysis of gastric cancer patients with diabetes mellitus","volume":"10","author":"Os\u00f3rio","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2026.124273_bb0170","doi-asserted-by":"crossref","first-page":"W415","DOI":"10.1093\/nar\/gkae456","article-title":"WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics","volume":"52","author":"Elizarraras","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lfs.2026.124273_bb0175","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.lfs.2026.124273_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073631","article-title":"Pirfenidone sensitizes NCI-H460 non-small cell lung cancer cells to paclitaxel and to a combination of paclitaxel with carboplatin","volume":"23","author":"Branco","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124273_bb0185","first-page":"19","article-title":"Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cells","volume":"7","author":"Matos","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.lfs.2026.124273_bb0190","first-page":"98","article-title":"Collateral sensitivity as a strategy against cancer multidrug resistance","volume":"15","author":"Pluchino","year":"2012","journal-title":"Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.lfs.2026.124273_bb0195","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/1120009X.2022.2097432","article-title":"Establishing and characterizing a novel doxorubicin-resistant acute myeloid leukaemia cell line","volume":"35","author":"Castro","year":"2023","journal-title":"J. Chemother."},{"key":"10.1016\/j.lfs.2026.124273_bb0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bmc.2011.11.042","article-title":"Solid-phase synthesis of 2\u2032-hydroxychalcones. Effects on cell growth inhibition, cell cycle and apoptosis of human tumor cell lines","volume":"20","author":"Neves","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.lfs.2026.124273_bb0205","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1385\/MB:26:3:249","article-title":"The comet assay for DNA damage and repair: principles, applications, and limitations","volume":"26","author":"Collins","year":"2004","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.lfs.2026.124273_bb0210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.dnarep.2005.09.010","article-title":"Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay","volume":"5","author":"Almeida","year":"2006","journal-title":"DNA Repair (Amst)."},{"key":"10.1016\/j.lfs.2026.124273_bb0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1747-0285.2010.00978.x","article-title":"Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone","volume":"76","author":"Palmeira","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.lfs.2026.124273_bb0220","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0959-8049(94)90187-2","article-title":"A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes","volume":"30a","author":"Twentyman","year":"1994","journal-title":"Eur. J. Cancer (Oxford, Engl. 1990)"},{"key":"10.1016\/j.lfs.2026.124273_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10937404.2024.2407452","article-title":"In vitro models to evaluate multidrug resistance in cancer cells: Biochemical and morphological techniques and pharmacological strategies","volume":"28","author":"Madrid","year":"2025","journal-title":"J. Toxic. Environ. Health, Part B"},{"key":"10.1016\/j.lfs.2026.124273_bb0230","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1038\/s41467-024-52441-z","article-title":"Drug-resistant cell lines in cancer","volume":"15","author":"Cinatl","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124273_bb0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2014.00040","article-title":"In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies","volume":"4","author":"McDermott","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2026.124273_bb0240","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.2910530321","article-title":"Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II)","volume":"53","author":"Yang","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2026.124273_bb0245","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/81.2.116","article-title":"Expression of multidrug resistance gene in human cancers","volume":"81","author":"Goldstein","year":"1989","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2026.124273_bb0250","first-page":"32","article-title":"Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression","volume":"70","author":"Yeh","year":"2003","journal-title":"Respir. Int. Rev. Thor. Dis."},{"key":"10.1016\/j.lfs.2026.124273_bb0255","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.biocel.2004.11.004","article-title":"Breast cancer resistance protein (BCRP\/ABCG2)","volume":"37","author":"Staud","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.lfs.2026.124273_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.607275","article-title":"Establishment and characterization of a topotecan resistant non-small cell lung cancer NCI-H460\/TPT10 cell line","volume":"8","author":"Lei","year":"2020","journal-title":"Front. Cell Develop. Biol."},{"key":"10.1016\/j.lfs.2026.124273_bb0265","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-010-0913-9","article-title":"Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol","volume":"137","author":"Sun","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lfs.2026.124273_bb0270","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.bbapap.2008.04.014","article-title":"Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line","volume":"1784","author":"Murphy","year":"2008","journal-title":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics."},{"key":"10.1016\/j.lfs.2026.124273_bb0275","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ijc.34783","article-title":"Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment","volume":"154","author":"Pelos","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2026.124273_bb0280","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/cells13050388","article-title":"Cancer drug resistance: targeting proliferation or programmed cell death","volume":"13","author":"Sazonova","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2026.124273_bb0285","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3727\/096504014X14098532393473","article-title":"Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer","volume":"22","author":"Shen","year":"2014","journal-title":"Oncol. Res."},{"key":"10.1016\/j.lfs.2026.124273_bb0290","first-page":"1","article-title":"Modulating ROS to overcome multidrug resistance in cancer","volume":"41","author":"Cui","year":"2018","journal-title":"Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.lfs.2026.124273_bb0295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbrc.2013.07.012","article-title":"Romo1 expression contributes to oxidative stress-induced death of lung epithelial cells","volume":"439","author":"Shin","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2026.124273_bb0300","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2007.05.088","article-title":"Drug resistance to 5-FU linked to reactive oxygen species modulator 1","volume":"359","author":"Hwang","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2026.124273_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770230","article-title":"Overexpression of reactive oxygen species modulator 1 predicts unfavorable clinical outcome in EGFR-mutant lung adenocarcinomas treated with targeted therapy","volume":"11","author":"Kwack","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2026.124273_bb0310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2014.11.004","article-title":"Reactive oxygen species modulator 1 (Romo1) overexpression is an independent predictor of poor survival in NSCLC patients who undergo surgical resection","volume":"87","author":"Lee","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lfs.2026.124273_bb0315","article-title":"Glutathione s-transferase mu-3 predicts a better prognosis and inhibits malignant behavior and glycolysis in pancreatic cancer","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2026.124273_bb0320","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/onc.2012.133","article-title":"Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src\/nuclear EGFR cascade-activated DNA repair activity","volume":"32","author":"Lee","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2026.124273_bb0325","first-page":"503","article-title":"Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells","volume":"34","author":"Doherty","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lfs.2026.124273_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2006.07.020","article-title":"Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance","volume":"173","author":"Yabuki","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.lfs.2026.124273_bb0335","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.139","article-title":"Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells","volume":"3","author":"Ajabnoor","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2026.124273_bb0340","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1023\/A:1008265012435","article-title":"Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol","volume":"9","author":"Perego","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2026.124273_bb0345","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/bjc.1997.154","article-title":"In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin","volume":"75","author":"Jensen","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2026.124273_bb0350","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.tiv.2008.04.005","article-title":"Development of taxane resistance in a panel of human lung cancer cell lines","volume":"22","author":"Breen","year":"2008","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.lfs.2026.124273_bb0355","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/bjc.2015.407","article-title":"Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin","volume":"113","author":"Colmegna","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2026.124273_bb0360","first-page":"160","article-title":"Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)","volume":"2","author":"Bonanno","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lfs.2026.124273_bb0365","first-page":"31","article-title":"Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells","volume":"7","author":"Lai","year":"1995","journal-title":"Oncol. Res."},{"key":"10.1016\/j.lfs.2026.124273_bb0370","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.dnarep.2016.02.004","article-title":"DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer","volume":"40","author":"Sears","year":"2016","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.lfs.2026.124273_bb0375","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bcp.2008.03.025","article-title":"Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy","volume":"76","author":"Clingen","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124273_bb0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41419-023-06256-3","article-title":"NPAS2 dampens chemo-sensitivity of lung adenocarcinoma cells by enhancing DNA damage repair","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2026.124273_bb0385","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.3390\/cancers16244218","article-title":"DNA damage response network and intracellular redox status in the clinical outcome of patients with lung cancer","volume":"16","author":"Mavroeidi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2026.124273_bb0390","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cllc.2011.04.005","article-title":"Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Roth","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lfs.2026.124273_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246068","article-title":"Platinum-resistant ovarian cancer is vulnerable to the cJUN-XRCC4 pathway inhibition","volume":"14","author":"Xu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2026.124273_bb0400","first-page":"145","article-title":"XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects","volume":"8","author":"Gu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.lfs.2026.124273_bb0405","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2010.05.010","article-title":"The platinum-based treatments for advanced non-small cell lung cancer, is low\/negative ERCC1 expression better than high\/positive ERCC1 expression? A meta-analysis","volume":"70","author":"Chen","year":"2010","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lfs.2026.124273_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.629266","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124273_bb0415","first-page":"414","article-title":"DNA direct reversal repair and alkylating agent drug resistance","volume":"4","author":"Gutierrez","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.lfs.2026.124273_bb0420","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1101\/gad.1897010","article-title":"Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer","volume":"24","author":"Oliver","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.lfs.2026.124273_bb0425","first-page":"4760","article-title":"Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy","volume":"55","author":"Zeng-Rong","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2026.124273_bb0430","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bbrc.2022.01.041","article-title":"Quantification of single-strand DNA lesions caused by the topoisomerase II poison etoposide using single DNA molecule imaging","volume":"594","author":"Singh","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2026.124273_bb0435","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cancergen.2020.12.002","article-title":"DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy","volume":"252-253","author":"de Almeida","year":"2021","journal-title":"Cancer Genet."},{"key":"10.1016\/j.lfs.2026.124273_bb0440","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/ijms26020796","article-title":"Etoposide as a key therapeutic agent in lung cancer: mechanisms, efficacy, and emerging strategies","volume":"26","author":"Jang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124273_bb0445","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14622416.9.1.105","article-title":"ABC multidrug transporters: structure, function and role in chemoresistance","volume":"9","author":"Sharom","year":"2008","journal-title":"Pharmacogenomics"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526000810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526000810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:01:29Z","timestamp":1774044089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":89,"alternative-id":["S0024320526000810"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124273","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidrug resistant non-small cell lung cancer cells exhibiting collateral sensitivity to DNA damaging drugs","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"124273"}}